Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06979076
PHASE1/PHASE2
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
Sponsor: MingSight Pharmaceuticals, Inc
View on ClinicalTrials.gov
Summary
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Official title: A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-07
Completion Date
2028-12
Last Updated
2025-09-29
Healthy Volunteers
No
Interventions
DRUG
MS-553, DS1
Oral, Dose Schedule 1
DRUG
MS-553, DS2
Oral, Dose Schedule 2